Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Solve Therapeutics has raised $50.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2024.
Solve Therapeutics's investors include General Atlantic, Decheng Capital, Surveyor Capital, Matrix Capital Management.
Solve Therapeutics is headquartered in Belmont, United States.
Solve Therapeutics is a biopharmaceutical company that develops Antibody Drug Conjugate and Bispecific Therapeutics.
Solve Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Solve Therapeutics — Funding & Investors." VCBacked, December 26, 2024, https://www.vcbacked.co/company/solve-therapeutics. Accessed August 14, 2026.
VCBacked. (2024). Solve Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/solve-therapeutics
{{cite web |title=Solve Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/solve-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated